Stock Events

Stock Events

Oryzon Genomics. 

$3.27
178
-$0.09-2.68% Friday 14:21

Statistics

Day High
3.45
Day Low
3.45
52W High
4.38
52W Low
3.25
Volume
100
Avg. Volume
378
Mkt Cap
261.23M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

22OctExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Q2 2026
Next
-0.08
-0.05
-0.03
0
Expected EPS
-0.0763288386
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
0Revenue
-3.07MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow ORYZF. It's not an investment recommendation.
Banco Santander.
43
SAN.MC
Repsol
42
REP.MC
Telefonica
36
TEF.MC
Grifols SA
32
GRF.MC

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Protagonist Therapeutics
PTGX
Mkt Cap9.34B
Protagonist Therapeutics, Inc. is involved in the discovery and development of innovative peptide-based drugs, overlapping with Oryzon's therapeutic areas.
CRISPR Therapeutics
CRSP
Mkt Cap5.58B
CRISPR Therapeutics AG specializes in gene editing, a cutting-edge area of biotechnology that could compete with Oryzon's genomic approaches.
Novartis
NVS
Mkt Cap292.35B
Novartis AG, through its extensive research in oncology and gene therapy, competes across multiple fronts with Oryzon's therapeutic developments.
Gilead Sciences
GILD
Mkt Cap180.64B
Gilead Sciences, Inc. is a major player in the development of innovative therapies, including oncology and inflammatory diseases, areas that Oryzon is also targeting.
AMGEN
AMGN
Mkt Cap233.78B
Amgen Inc. has a broad portfolio in biotechnology treatments, including oncology and hematology, competing with Oryzon's research and development focus.
Vertex Pharmaceuticals
VRTX
Mkt Cap137.3B
Vertex Pharmaceuticals Incorporated is known for its work in treating genetic diseases, potentially competing with Oryzon's genomic and epigenetic approaches.
Biomarin Pharmaceutical
BMRN
Mkt Cap12.52B
BioMarin Pharmaceutical Inc. specializes in enzyme replacement therapies and rare genetic diseases treatment, overlapping with Oryzon's focus on innovative and targeted therapies.

About

Oryzon Genomics S.A. is a clinical-stage biopharmaceutical company dedicated to advancing epigenetics-based therapies for individuals battling cancer and central nervous system (CNS) conditions. The company's clinical pipeline features two key compounds. Iadademstat (ORY-1001), a selective LSD1 inhibitor, is currently undergoing Phase II trials for various oncological indications. Similarly, vafidemstat (ORY-2001), another LSD1 inhibitor specifically designed for CNS applications, is also in Phase II for the treatment of neurological and psychiatric illnesses. Furthermore, ORY-3001, an LSD1 inhibitor, is progressing through preclinical development with the aim of addressing non-cancerous diseases. Established in 2000, Oryzon Genomics is headquartered in Cornellà de Llobregat, Spain.
Show more...
CEO
Carlos Manuel Buesa Arjol
Employees
46
Country
Spain
ISIN
ES0167733015
WKN
000A2ACV2

Listings

F
DE
ORN.F
STU
DE
ORN.STU
LSE
GB
0RDB.LSE
MU
DE
ORN.MU

0 Comments

Share your thoughts

FAQ

What is Oryzon Genomics. stock price today?▼
The current price of ORYZF is $3.27 USD — it has decreased by -2.68% in the past 24 hours. Watch Oryzon Genomics. stock price performance more closely on the chart.
What is Oryzon Genomics. stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on OTC Link exchange Oryzon Genomics. stocks are traded under the ticker ORYZF.
What is Oryzon Genomics. market cap?▼
Today Oryzon Genomics. has the market capitalization of 261.23M
When is the next Oryzon Genomics. earnings date?▼
Oryzon Genomics. is going to release the next earnings report on October 22, 2026.
What were Oryzon Genomics. earnings last quarter?▼
ORYZF earnings for the last quarter are 0 USD per share, whereas the estimation was -0.06 USD resulting in a +100% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Oryzon Genomics. revenue for the last year?▼
Oryzon Genomics. revenue for the last year amounts to 0 USD.
What is Oryzon Genomics. net income for the last year?▼
ORYZF net income for the last year is -3.07M USD.
How many employees does Oryzon Genomics. have?▼
As of September 04, 2026, the company has 46 employees.
In which sector is Oryzon Genomics. located?▼
Oryzon Genomics. operates in the Health & Wellness sector.
When did Oryzon Genomics. complete a stock split?▼
Oryzon Genomics. has not had any recent stock splits.
Where is Oryzon Genomics. headquartered?▼
Oryzon Genomics. is headquartered in Cornellà de Llobregat, Spain.